Group 1 - The China Securities Regulatory Commission has issued a notice regarding the overseas issuance and listing of Shanghai Baoji Pharmaceutical Co., Ltd., allowing the company to issue up to 110,426,740 overseas listed ordinary shares and list them on the Hong Kong Stock Exchange [1] - A total of 46 shareholders plan to convert 116,415,550 shares of unlisted domestic shares into overseas listed shares for trading on the Hong Kong Stock Exchange [1] Group 2 - Baoji Pharmaceutical is a clinical-stage biotechnology company focused on developing and providing recombinant biopharmaceuticals in China, utilizing synthetic biology technology [3] - The company has established a pipeline of seven clinical-stage drug candidates, including three core products (KJ017, KJ103, and SJ02), and five preclinical assets, covering four therapeutic areas [3] - The company's core products are protected by comprehensive intellectual property rights, including nine granted patents and ten patent applications [3] - The proprietary technology platform supports the development of drug candidates in four strategic therapeutic areas, with a projected market size exceeding RMB 50 billion by 2033 [3]
新股消息 | 宝济药业港股IPO及境内未上市股份“全流通”获中国证监会备案
智通财经网·2025-10-29 11:52